These findings suggest that oridonin may exert anti-cancer effects through the EGFR/PI3K/AKT signalling pathway, providing a robust theoretical foundation for its clinical application and mechanistic investigation in HCC treatment. Here, AKT1 is linked to hepatocellular carcinoma.